Originals

European Journal of Clinical Pharmacology

, Volume 46, Issue 5, pp 399-404

First online:

Esmolol, an ultrashort-acting, selective β1-adrenoceptor antagonist: pharmacodynamic and pharmacokinetic properties

  • C. Volz-ZangAffiliated withZentrum der Pharmakologie, Klinikum der Johann-Wolfgang-Goethe-Universität
  • , B. EckrichAffiliated withZentrum der Pharmakologie, Klinikum der Johann-Wolfgang-Goethe-Universität
  • , P. JahnAffiliated withZentrum der Pharmakologie, Klinikum der Johann-Wolfgang-Goethe-Universität
  • , B. SchneidrowskiAffiliated withZentrum der Pharmakologie, Klinikum der Johann-Wolfgang-Goethe-Universität
  • , B. SchulteAffiliated withKerckhoff-Klinik der Max-Planck-Gesellschaft
  • , D. PalmAffiliated withZentrum der Pharmakologie, Klinikum der Johann-Wolfgang-Goethe-Universität

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

The effects of esmolol at different rates of infusion (100, 250 and 500 μg·kg−1 BW·min−1) were compared with β-adrenoceptor occupancy (β1 and β2, estimated by a subtype selective radioreceptor assay) and plasma concentrations of esmolol and its acid metabolite were measured by HPLC. Up to a rate of infusion of esmolol of 500 μg·kg−1 BW·min−1 there was a maximal β1-receptor occupancy of 84.7% while β2-receptor occupancy was below the detection limit; confirming the β1 selectivity of esmolol. Exercise-induced increases in heart rate and systolic blood pressure were reduced by esmolol in a dose-dependent manner. The estimated EC50 values of rate of infusion for the reduction in heart rate and systolic blood pressure during exercise were 113 and 134 μg·kg−1 BW · min−1, respectively. Additionally, heart rate and systolic blood pressure were reduced moderately at rest. Because of the short elimination half-life of esmolol caused by the rapid hydrolysis to its acid metabolite, 45 min after end of infusion high plasma concentrations of the metabolite (maximally 80 μg·ml−1) but no esmolol were detectable. Since no in vivo effects have been observed, despite the presence of high plasma concentrations of the metabolite, the metabolite did not participate in the observed effects up to an infusion rate of esmolol of 500 μg·kg−1 BW·min−1. The plasma concentrations of antagonist detected by radioreceptor assay and plasma concentrations of esmolol detected by HPLC showed a good correlation (r=0.97). Since the cardiovascular effects, determined before and 45 min after termination of infusion of esmolol were similar, it can be concluded that the observed effects on heart rate and systolic blood pressure are exclusively mediated by esmolol.

Key words

Esmolol β1-Adrenoceptor antagonist tricresylphosphate pharmacokinetics effect kinetics